rs11614913 polymorphism in miRNA-196a2 and cancer risk: an updated meta-analysis

• Main Authors: Liu Y, He A, Liu B, Zhong Y, Liao X, Yang J, Chen J, Wu J, Mei H
• Format: Article
• Language: English
• Published: Dove Medical Press 2018-03-01
• Series: OncoTargets and Therapy
• Subjects: MiR-196a2; Rs11614913; Polymorphisms; Cancer risk; Meta-analysis.
• Online Access: https://www.dovepress.com/rs11614913-polymorphism-in-mirna-196a2-and-cancer-risk-an-updated-meta-peer-reviewed-article-OTT

Yuhan Liu,1,* Anbang He,1,2,* Baoer Liu,1 Yucheng Zhong,1 Xinhui Liao,1 Jiangeng Yang,1 Jieqing Chen,1 Jianting Wu,1 Hongbing Mei1 1Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China; 2Department of Urology, Peking University First Hospital, The Institute of Urology, Peking University, National Urological Cancer Centre, Beijing, China *These authors contributed equally to this work Abstract: Several epidemiological studies have reported that polymorphisms in microRNA-196a2 (miR-196a2) were associated with various cancers. However, the results remained unverified and were inconsistent in different cancers. Therefore, we carried out an updated meta-analysis to elaborate the effects of rs11614913 polymorphism on cancer susceptibility. A total of 84 articles with 35,802 cases and 41,541 controls were included to evaluate the association between the miR-196a2 rs11614913 and cancer risk by pooled odds ratios (ORs) and 95% confidence intervals (CIs). The results showed that miR-196a2 rs11614913 polymorphism is associated with cancer susceptibility, especially in lung cancer (homozygote comparison, OR =0.840, 95% CI =0.734–0.961; recessive model, OR =0.858, 95% CI =0.771–0.955), hepatocellular carcinoma (allelic contrast, OR =0.894, 95% CI =0.800–0.998; homozygote comparison, OR =0.900, 95% CI =0.813–0.997; recessive model, OR =0.800, 95% CI =0.678–0.944), and head and neck cancer (allelic contrast, OR =1.076, 95% CI =1.006–1.152; homozygote comparison, OR =1.214, 95% CI =1.043–1.413). In addition, significant association was found among Asian populations (allele model, OR =0.847, 95% CI =0.899–0.997, P=0.038; homozygote model, OR =0.878, 95% CI =0.788–0.977, P=0.017; recessive model, OR =0.895, 95% CI =0.824–0.972, P=0.008) but not in Caucasians. The updated meta-analysis confirmed the previous results that miR-196a2 rs11614913 polymorphism may serve as a risk factor for patients with cancers. Keywords: miR-196a2, polymorphisms, cancer risk, meta-analysis